← Back to updates
Emerging treatmentsCompany-reported Phase 3 resultDid not meet its main goal

Completed Phase 3 study in people; company-reported main result, no full results posted

Tolebrutinib: Phase 3 PERSEUS study in primary progressive MS did not meet its main goal

Published by MyelinWatch:

What happened

On 15 December 2025, Sanofi announced that its Phase 3 PERSEUS study (NCT04458051) of tolebrutinib in primary progressive multiple sclerosis (MS) did not meet its main goal: tolebrutinib was not shown to delay the time to disability progression confirmed over six months, compared with placebo. That measure combines worsening on the EDSS disability scale, a timed 25-foot walk and a hand-dexterity test. The registry lists 767 participants; according to Sanofi, people aged 18 to 55 were assigned two to one to daily tolebrutinib tablets or placebo for up to about five years. Sanofi said that the preliminary safety profile was consistent with earlier tolebrutinib studies and that drug-induced liver injury is an identified risk of the drug. Based on these results, Sanofi said it will not seek regulatory approval of tolebrutinib for primary progressive MS. The announcement gives no figures. On 11 November 2026, ClinicalTrials.gov listed the study as completed on 14 November 2025, with no results posted.

What this means for people with MS

For people with primary progressive MS, this Phase 3 study did not show that tolebrutinib slows disability progression, and Sanofi does not plan to seek approval for that form of MS. The result does not change the separate EU authorisation of Cenrifki (tolebrutinib) for adults with secondary progressive MS without relapses in the previous two years, which rests on a different study, HERCULES. Because only a short company statement is available, the size of any difference, the secondary results and the full safety data cannot be assessed. The study had centres in many countries, including Greece; it has ended and is not accepting participants.

About the approach studied in this programme: Tolebrutinib / Cenrifki

Tolebrutinib is an oral inhibitor of Bruton’s tyrosine kinase (BTK), a signalling protein in immune cells. The approach aims to reduce inflammatory activity in MS, including processes linked to disability progression; it has not been shown to restore myelin.

Approach source: EMA — Cenrifki medicine overview ↗

What kind of evidence exists?
Official Sanofi announcement; study design and completion from ClinicalTrials.gov and the EU clinical trials register
How reliable is this source?
Official Sanofi announcement for the main result, the safety statement and the decision not to seek approval; ClinicalTrials.gov and the EU Clinical Trials Information System for study design, size, countries and completion. The announcement contains no numerical results; no registry results and no peer-reviewed PERSEUS report were found on 11 November 2026.
Source: Sanofi — official company announcement ↗Source: ClinicalTrials.gov — PERSEUS NCT04458051, completed, no results posted ↗ Source: EU Clinical Trials Information System — PERSEUS 2024-514495-41-00, ended ↗
Research event/source date
Published by MyelinWatch
Last substantive MyelinWatch update

Related substantive developments

Research event/source date:
Emerging treatmentsRegistered study in peopleRegistered study plan; no results

Registered Phase 1/2 study; not yet accepting participants; start estimated for January 2027

UKT-CART19.1: a CAR-T study in autoimmune diseases including MS was registered in Tübingen

Organisation: University Hospital Tübingen · Germany

ClinicalTrials.gov first posted NCT07932262 on 12 November 2026. The sponsor is University Hospital Tübingen in Germany. This is a single-centre, open-label Phase 1/2 study with one treatment group. It tests UKT-CART19.1, CAR-T cells made from the person's own T cells and aimed at CD19, a marker on B cells. The same treatment, given as one infusion, is tested in adults aged 18 to 80 with seven relapsed or treatment-resistant autoimmune diseases, one of which is multiple sclerosis (MS). People with MS must have had recent disease activity (a relapse, worsening or new MRI activity in the previous 24 months) and must not have responded to at least two high-potency MS medicines (category 3 in the German guideline). The registry estimates 36 participants in total for all diseases and does not say how many will have MS. The main outcome is safety over 6 months. The EU clinical trials register (CTIS) shows authorisation in Germany on 14 August 2026. ClinicalTrials.gov lists the study as not yet accepting participants, with an estimated start in January 2027.

Published by MyelinWatch:

What this means for people with MS

Registration and authorisation describe a study plan. They do not show that anyone has been enrolled or treated, or that UKT-CART19.1 works or is safe in MS, and no results are posted. The estimated start differs between the two records (recruitment from 1 July 2026 in CTIS, January 2027 on ClinicalTrials.gov), and neither shows that recruitment has begun. The study has one centre, in Tübingen, and neither record lists a site in Greece, so it is not an established route to treatment for people in Greece. Eligibility is decided by the study team, whose contacts are in the registry. Participants are to be followed for up to 15 years, as required for gene-therapy studies.

Research event/source date:
Emerging treatments + myelin repairRegistered study in peopleFirst participant dosed; no results posted

Combined early Phase 1/2a study in people; no results posted

PRO-1562: Progentos reports first participant dosed in an early study of a possible myelin-repair drug

Organisation: Progentos Therapeutics · United States

On 3 November 2026, Progentos Therapeutics announced that the first participant has been dosed in its Phase 1/2a study of PRO-1562 (NCT07826689), an experimental oral small molecule designed to repair myelin in multiple sclerosis (MS). The company did not give the dosing date or say in which part of the study this happened. It describes the Phase 1 part as placebo-controlled single rising doses in healthy adults at one site in Australia, so the announcement does not show whether that participant received PRO-1562 or placebo. The later Phase 2a part plans six months of once-monthly doses or placebo in adults with relapsing MS and chronic optic neuropathy. The company says that the drug promoted myelin repair in laboratory and animal studies; it reports no human results. The ClinicalTrials.gov record, last updated on 29 September 2026 and checked on 6 November, still shows the study as accepting participants, an estimated October 2026 start and no posted results.

Published by MyelinWatch:

What this means for people with MS

According to the company, this study has started dosing. That does not show that PRO-1562 is safe, that it repairs myelin in people or that it helps people with MS. Laboratory and animal results may not apply to people. The announcement does not establish that the MS part has opened. PRO-1562 is an experimental drug, not an available treatment. The registry lists one site, in Adelaide, Australia, and none in Greece. No established approved treatment in clinical practice has been proven to reliably restore myelin in MS.

Research event/source date:
Emerging treatmentsRegistered study in peopleStudy authorised in Greece; not a result

Phase 3 extension study authorised in Greece; recruitment not yet started

Frexalimab: Greece authorises the long-term Phase 3 extension study

Organisation: Sanofi · France

The EU Clinical Trials Information System (CTIS) shows that Greece authorised Sanofi's Phase 3 extension study LTS18002 (2026-525688-41-00) on 2 November 2026. Denmark, Portugal and Poland authorised it on the same day, after Belgium (30 October 2026) and Austria (1 November 2026); all six countries are listed as authorised with recruitment pending. The record plans 17 participants in Greece and lists four Greek hospitals: AHEPA University General Hospital of Thessaloniki, the University General Hospital of Ioannina, the General University Hospital of Larissa and the 401 General Military Hospital of Athens. The study will look at the long-term safety and tolerability of frexalimab, an experimental antibody, in people with multiple sclerosis (MS). It is open only to people who complete earlier frexalimab studies on the study drug, such as the Phase 3 studies FREXALT and FREVIVA. The estimated EU recruitment start is 15 February 2027.

Published by MyelinWatch:

What this means for people with MS

Authorisation means the study may proceed in Greece; it does not mean that it has started at any Greek hospital, that anyone has received treatment in it, or that frexalimab works. No Phase 3 results are available yet. People who are not already in a frexalimab study cannot join this extension, so it is not a way for other people with MS in Greece to receive frexalimab. Frexalimab is not an available treatment in Greece.